Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and dose-expansion study of AZD4360 in CLDN18.2-positive advanced solid tumors
CTR20251223Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD4360 in pancreatic adenocarcinoma (PDAC), gastric cancer (GC), esophagogastric junction cancer, biliary cancer, sponsored by AstraZeneca. Started May 2025; status: terminated.
02
Drugs
AZD4360
03
Conditions
pancreatic adenocarcinoma (PDAC)gastric cancer (GC)esophagogastric junction cancerbiliary cancer
Beyond the preview
Go deeper on CTR20251223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251223.